Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Report: Biosimilars Will Benefit U.S. Drug Channel

By Pharmaceutical Processing | October 7, 2013

Biosimilars will have a positive impact on the dynamics of the U.S. drug channel, similar to but initially less pronounced than that of generic pharmaceuticals, according to a new Fitch Ratings report.

Biosimilars will likely present a compelling margin expansion opportunity for most drug channel participants, excluding originators. Fitch expects specialty drug distributors, specialty pharmacies, pharmacy benefit managers (PBMs), and payors to each capture a component of the cost savings derived from switching to lower cost drug alternatives from often very expensive biologic drugs.

Fitch expects these participants to be aggressive in encouraging and facilitating the conversion of branded biologics to biosimilars. Overall biosimilar uptake is likely to be more rapid in the U.S. than that seen in Europe to-date. However, physicians will retain substantial influence over the rate at which these conversions take place due to significant differences between traditional generics and biosimilars.

Biopharma developers are not without defenses. Many manufacturers of novel biologics are also engaged in the development of biosimilars. ‘Biobetters’ and next-generation version of current biological therapies are also strategies for hedging the risk associated with a biologic drug’s patent expiration.

The full report, ‘Trekking the Path to Biosimilars – The Destination’ is available at ‘ www.fitchratings.com ‘. This is the fourth and final report in a series dedicated to the burgeoning global biosimilars market.

Additional information is available at ‘ www.fitchratings.com

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards